リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Automated screening procedure for the phenotypes of congenital fibrinogen disorders using novel parameters, |min1|c and Ac/|min1|c, obtained from clot waveform analysis using the Clauss method」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Automated screening procedure for the phenotypes of congenital fibrinogen disorders using novel parameters, |min1|c and Ac/|min1|c, obtained from clot waveform analysis using the Clauss method

Arai, Shinpei Kamijo, Tomu Kaido, Takahiro Yoda, Masahiro Shinohara, Sho Suzuki, Takeshi Arai, Nobuo Sugano, Mitsutosho Uehara, Takeshi Okumura, Nobuo 信州大学 DOI:34273336

2022.01.04

概要

Introduction: Fibrinogen activity (Ac) is widely measured, but fibrinogen antigen (Ag) is measured only in specialized laboratories, so it is difficult to discriminate congenital fibrinogen disorders (CFDs) from acquired hypofibrinogenemia (aHypo). In this study, to screen for CFD phenotypes we adopted novel parameters, |min1|c and Ac/ |min1|c, and compared these with validated Ac, Ag, and Ac/Ag, and previously proposed Ac/dH and Ac/|min1|.

Materials and Methods: We calibrated |min1| using a CN-6000 instrument and investigated the correlation between Ag and |min1|c for aHypo (n=131) and CFD [18 dysfibrinogenemia (Dys), two hypodysfibrinogenemia (Hypodys) and four hypofibrinpogenemia (Hypo)]. Furthermore, we proposed a schema for screening CFD phenotypes using |min1|c and Ac/|min1|c.

Results: The |min1|c correlated well with Ag in aHypo, and Ac/|min1|c was a better parameter for screening Dys and Hypodys than Ac/dH and Ac/|min1|. With the combination of |min1|c and Ac/|min1|c parameters, 15 Dys, 2 Hypodys and four Hypo were categorized in agreement with the phenotype determined using Ag and Ac/Ag; conversely three Dys were classified as one Hypodys (AαR16C) and two Hypo (BβG15C).

Conclusion: We demonstrated that |min1|c and Ac/|min1|c are valuable parameters for screening CFD patients and phenotypes in laboratories that do not measure Ag or perform genetic analysis.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

[1] C.M. Redman, H. Xia, Fibrinogen biosynthesis. Assembly, intracellular degradation, and association with lipid synthesis and secretion, Ann. N. Y. Acad. Sci. 936 (2001) 480– 495.

[2] G.A. Tennent, S.O. Brennan, A.J. Stangou, J. O'Grady, P.N. Hawkins, M.B. Pepys, Human plasma fibrinogen is synthesized in the liver, Blood. 109 (2007) 1971-1974.

[3] MW. Mosesson, Fibrinogen and fibrin structure and functions, J. Thromb. Haemost. 3 (8) (2005) 1894–1904.

[4] P. De Moerloose, A. Casini, M. Neerman-Arbez, Congenital fibrinogen disorders: an update, Semin. Thromb. Hemost. 39 (6) (2013) 585–595.

[5] A. Casini, M. Neerman-Arbez, RA. Ariëns, P. De Moerloose, Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management, J. Thromb. Haemost. 13 (6) (2015) 909–919.

[6] Groupe d’etude sur l’hemostase et la thrombose. Human fibrinogen database. 2018. https://site.geht.org/base-de-donnees-fibrinogene/, (accessed 30 March 2021).

[7] A. Casini, A. Undas, R. Palla, J. Thachil, P. de Moerloose, Subcommittee on Factor XIII and Fibrinogen, Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH, J Thromb Haemost. 16 (9) (2018) 1887-1890.

[8] A. Casini, M. Neerman-Arbez, R.A. Ariëns, P. de Moerloose, Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management, J. Thromb. Haemost. 13 (6) (2015) 909-919.

[9] A. Casini, P. de Moerloose, Congenital Fibrinogen Disorders Group, Management of congenital quantitative fibrinogen disorders: a Delphi consensus, Haemophilia. 22 (6) (2016) 898-905.

[10] G. Burcu, E. Bellacchio, E. Sag, A.H. Cebi, I. Saygin, A.Bahadir, G. Yilmaz, M. Corbeddu, M. Cakir, F. Callea, Structural Characteristics in the γ Chain Variants Associated with Fibrinogen Storage Disease Suggest the Underlying Pathogenic Mechanism, Int J Mol Sci. 21 (14) (2020) 5139, https://doi.org/10.3390/ijms21145139.

[11] T. Kobayashi, S. Arai, N. Ogiwara, Y. Takezawa, M. Nanya, F. Terasawa, N. Okumura, γ375W fibrinogen-synthesizing CHO cells indicate the accumulation of variant fibrinogen within endoplasmic reticulum, Thromb Res. 133 (1) (2014) 101-107.

[12] S. Arai, N. Ogiwara, S. Mukai, Y. Takezawa, M. Sugano, T. Honda, N. Okumura, The fibrous form of intracellular inclusion bodies in recombinant variant fibrinogen- producing cells is specific to the hepatic fibrinogen storage disease-inducible variant fibrinogen, Int J Hematol. 105 (6) (2017) 758-768.

[13] A. Clauss, Rapid physiological coagulation method in determination of fibrinogen, Acta Haematol. 17 (4) (1957) 237-246.

[14] V Chantarangkul, A Tripodi, P.M. Mannucci, Evaluation of a fully automated centrifugal analyzer for performance of hemostasis tests, Clin Chem. 33 (10) (1987) 1888-1890.

[15] E. Rossi, P. Mondonico, A. Lombardi, L. Preda, Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers, Thromb.Res. 52 (5) (1988) 453-468.

[16] M. Shima, J. Thachil, S.C. Nair, A. Srivastava, Scientific and Standardization Committee, Towards standardization of clot waveform analysis and recommendations for its clinical applications, J Thromb Haemost. 11 (7) (2013) 1417-1420.

[17] A. Suzuki, N. Suzuki, T. Kanematsu, S. Shinohara, N. Arai, R. Kikuchi, T. Matsushita, Clot waveform analysis in Clauss fibrinogen assay contributes to classification of fibrinogen disorders, Thromb Res. 174 (2019) 98-103.

[18] S. Arai, T. Kamijo, F. Hayashi, S. Shinohara, N. Arai, M. Sugano, T. Uehara, T. Honda, N. Okumura, Screening method for congenital dysfibrinogenemia using clot waveform analysis with the Clauss method, Int J Lab Hematol. 43 (2) (2021) 281-289.

[19] F. Terasawa, N. Okumura, K. Kitano, N. Hayashida, M. Shimosaka, M. Okazaki, et al, Hypofibrinogenemia associated with a heterozygous missense mutation gamma153Cys to Arg (Matsumoto IV): in vitro expression demonstrates defective secretion of the variant fibrinogen, Blood. 94 (12) (1999) 4122–4131.

[20] Y. Kanda, Investigation of the freely available easy-to-use software “EZR” for medical statistics, Bone Marrow Transplant. 48 (3) (2018) 452–458.

[21] WJ. Youden, Index for rating diagnostic tests, Cancer. 3 (1) (1950) 32-35.

[22] M. Hirota-Kawadobora, F. Terasawa, O. Yonekawa, N. Sahara, E. Shimizu, N. Okumura, T. Katsuyama, H. Shigematsu, Fibrinogens Kosai and Ogasa: Bbeta15Gly→Cys (GGT→TGT) substitution associated with impairment of fibrinopeptide B release and lateral aggregation, J Thromb Haemost. 1 (2) (2003) 275-283.

[23] T. Kaido, M.Yoda, T. Kamijo, C. Taira, Y. Higuchi, N. Okumura, Comparison of molecular structure and fibrin polymerization between two Bβ-chain N-terminal region fibrinogen variants, Bβp.G45C and Bβp.R74C, Int J Hematol. 112 (3) (2020) 331-340.

[24] K. Soya, Y. Takezawa, F. Terasawa, N. Okumura, Functional analysis for dysfibrinogenemias, Toyama and Adachi, which have a mutation of Aalpha16Arg-->His (CGT-->CAT) with aberrant fibrinopeptide A release, Rinsho Byori. 60 (6) (2012) 499-505.

[25] Y. Kamijyo, M. Hirota-Kawadobora, N. Fujihara, S.Wakabayashi, K. Matsuda, K. Yamauchi, F. Terasawa, N. Okumura, T. Honda, Functional analysis of heterozygous plasma dysfibrinogens derived from two families of gammaArg275Cys and three families of gammaArg275His, and haplotype analysis for these families, Rinsho Byori. 57 (7) (2009) 651-658.

[26] RF. Doolittle, Fibrinogen and fibrin, Annu Rev Biochem. 53 (1984) 195-229.

[27] Z. Yang, I. Mochalkin, RF. Doolittle, A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides, Proc Natl Acad Sci U S A. 97 (26) (2000) 14156-14161.

[28] MW. Mosesson, KR. Siebenlist, JP. DiOrio, M. Matsuda, JF. Hainfeld, JS. Wall, The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (gamma 275 Arg-->Cys), J Clin Invest. 96 (2) (1995) 1053-1058.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る